Curatis licenses corticorelin to Neupharma in CHF 83.5m Japan deal
Curatis and Neupharma sign a CHF 83.5m Japan licensing deal for corticorelin in peritumoral brain edema. Read our analysis of what the deal means.
Why Daiichi Sankyo is betting early on SylamoreBio’s SyLEC delivery platform for CNS programs
SylamoreBio partners with Daiichi Sankyo to test SyLEC CNS delivery technology. Find out what this collaboration changes for brain drug development.